Didanosine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
The following adverse reactions are discussed in greater detail in other sections: | The following adverse reactions are discussed in greater detail in other sections<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = 1 January 2014 }}</ref>: | ||
*:[[Pancreatitis]] | *:[[Pancreatitis]] | ||
*: Lactic acidosis/severe hepatomegaly with steatosis | *: Lactic acidosis/severe hepatomegaly with steatosis | ||
*: Hepatic toxicity | *: Hepatic toxicity | ||
*: Non-cirrhotic portal hypertension | *: Non-cirrhotic portal hypertension. | ||
*: [[Peripheral neuropathy]] | *: [[Peripheral neuropathy]]. | ||
*: Retinal changes and [[optic neuritist]] | *: Retinal changes and [[optic neuritist]]. | ||
==References== | ==References== | ||
Revision as of 20:26, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections[1]:
- Lactic acidosis/severe hepatomegaly with steatosis
- Hepatic toxicity
- Non-cirrhotic portal hypertension.
- Retinal changes and optic neuritist.
References
- ↑ "VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY]". Retrieved 1 January 2014.
Adapted from the FDA Package Insert.